N/A N=160 Patient-Centered Care for the Older Adult With Hematologic Malignancy
Hematologic Malignancy
Primary: Overall Survival — 79; 49 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only) — 7.8 10^9 Neutrophils per Liter
Phase 2 N=100 Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial
Whole Blood Donation and Leukoreduction
Primary: % of Red Blood Cells With Hemolysis — 0.29; 0.29 % of Red Blood Cells with Hemolysis
N/A N=664 Clinical Utility of Postoperative Hemoglobin Testing
Anaemia Postoperative
Primary: Number of Subjects With POD1 Hemoglobin Less Than 10 g/dL — 97 Participants
Phase 2 N=27 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Acute Myelocytic Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Safety and Tolerability of HSC835 for Clinical Use Were Measured by Infusional Toxicity (Within First 48 Hours After Transplant) and Absence of Graft Failure After 32…
N/A N=22 Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
Hematologic Neoplasms · Burns
Primary: Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion. — 2; 3 Participants
N/A N=88 Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
Hemorrhage
Primary: CBC Hemoglobin Measurement Compared to Non-invasive Radical-7 Measurement — 10.7; 9.2 grams per deciliter
N/A N=131 Noninvasive Hemoglobin Testing, Prospective Blood Donors
Healthy · Anemia
Primary: Rad-67 Sensitivity — 44 percentage of sensitivity
N/A N=41 An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
Hematologic Malignancies
Primary: Retention Rate — 38; 3 Participants
N/A N=30 Exercise Prehab in Older Adults With Hematologic Malignancies
Hematopoietic and Lymphoid Cell Neoplasm
Primary: Number of Patients With Adverse Events (AE), Graded According to Common Terminology Criteria for Adverse Events Version 5.0 — 0 Participants
N/A N=18 Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Phase 3 N=22 Stem Cell Transplant for Hemoglobinopathy
Sickle Cell Disease · Thalassemia · Severe Congenital Neutropenia
Primary: Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity — 0; 0; 2 Participants
Phase 2 N=29 HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Sickle Cell Disease · Beta Thalassemia-Major
Primary: Number of Participants With Sustained Cell Engraftment of Donor Cells — 29 Participants
N/A N=62 Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder
Transmission, Blood, Recipient/Donor
Primary: Plasma Supernatant Hemoglobin — 26.8; 28.0 mg/dL
Phase 2 N=34 Reduced Intensity Haploidentical Transplant for Hematological Malignancies
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Phase 2 N=20 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Graft Versus Host Disease · Leukemia · Lymphoma
Primary: Overall Response Rate — 12; 1; 7 Participants
N/A N=62 Intelligent Control Approach to Anemia Management
End-Stage Renal Disease
Primary: Percent Hb 10-12 g/dL — 61.9; 72.5 Percent
N/A N=112 Sickle Cell Anemia WE CARE
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
N/A N=104 Multidisciplinary Evaluation of Patients With Hemophilia
Haemophilia
Primary: Assess the Joint Damage — 0.36; 0 points
N/A N=150 Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders
Hematologic Disorders
Primary: The Number of Patients With Successful Engraftment — 144 Participants
N/A N=32 Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure
Multiple Myeloma
Primary: Days Until Neutrophil Recovery Following Peripheral Blood Stem Cell Transplant Minus the Historical Median Day Until Recovery. — 0 Days — p=<0.025
Phase 2 N=2 Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
Hemoglobinopathies · Sickle Cell Disease · Thalassemia
Primary: Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy. — 2 participants
Phase 1 N=58 Study of MLN8237 in Participants With Advanced Hematological Malignancies
B-cell Follicular Lymphoma · B-cell Marginal Zone Lymphoma · Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 1; 2; 0; 1 participants
N/A N=100 Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute
Primary: Survial Rate at 30 Days — 100; 97 percentage of participants
N/A N=703 Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Percentage Analyzed Participants Receiving Hematopoietic Stem Cell Transplantation (HCT) — 44.7 % participants
N/A N=10 Blood Volume and Fluid Kinetics in Patients Undergoing Extracorporal Circulation
Blood Volume, Extravasation
Primary: Blood Volume — 4.61 Litre
N/A N=60 Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Efficacy of 1020 mg of Ferumoxytol Over 15 Minutes. Hemoglobin Measurements Will Take Place at Four and Eight Week Visit. — 85; 58; 92; 86 percentage of participants
N/A N=372 Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
Hematologic Diseases
Primary: Caregiver Health-related Quality of Life (HRQOL) Assessed by the PROMIS Global Health Scale. — 48.18; 48.16 score on a scale
N/A N=52 Hemosonics- VCU Cardiac Surgery Clinical Study
Cardiopulmonary Bypass
Primary: Clot Time — 4.9; 3.3 min — p=<0.001
N/A N=31 Daxor - Blood Volume Analysis
Heart Failure · Congestive Heart Failure
Primary: Change in Whole Blood Volume — -1253; -784 mL — p=>0.05